MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$1,051K
Net Income
-$30,359K
Net Profit Margin
-2888.58%
EPS
-$0.23
Unit: Thousand (K) dollars
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Collaboration and license revenue
1,051
982
2,567
2,511
Research and development
23,402
21,904
20,039
31,689
General and administrative
8,142
8,217
6,386
7,874
Total operating expenses
31,544
30,121
26,425
39,563
Loss from operations
-30,493
-29,139
-23,858
-37,052
Interest and other income, net
833
1,162
1,583
2,041
Interest expense
699
689
702
699
Total other income
134
473
881
1,342
Net loss
-30,359
-28,666
-22,977
-35,710
Unrealized loss on available-for-sale securities
0
0
-51
-
Comprehensive loss
-30,359
-28,666
-23,028
-
Basic EPS
-0.23
-0.22
-0.177
-0.28
Diluted EPS
-0.23
-0.22
-0.177
-0.28
Basic Average Shares
129,948,878
129,913,376
129,864,699
129,835,938
Diluted Average Shares
129,948,878
129,913,376
129,864,699
129,835,938
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Comprehensive loss
-$30,359K
Interest and other
income, net
$833K
(-65.15%↓ Y/Y)
Net loss
-$30,359K
(17.84%↑ Y/Y)
Total other income
$134K
(-92.12%↓ Y/Y)
Interest expense
$699K
(1.45%↑ Y/Y)
Loss from operations
-$30,493K
(21.11%↑ Y/Y)
Collaboration and license
revenue
$1,051K
(-65.83%↓ Y/Y)
Total operating
expenses
$31,544K
(-24.41%↓ Y/Y)
Research and development
$23,402K
(-28.29%↓ Y/Y)
General and
administrative
$8,142K
(-10.48%↓ Y/Y)
Buy us a coffee
TScan Therapeutics, Inc. (TCRX)
TScan Therapeutics, Inc. (TCRX)